Amarin’s announcement last night that the FDA plans to hold an advisory committee meeting, tentatively scheduled for November 14, came as a surprise, Cantor Fitzgerald analyst Louise Chen tells investors in a research note titled “No Heartbreak Here, Negative Reaction To AdCom Is Overdone, In Our View.” That being said, the stock weakness in reaction to the news is overdone, says Chen. Amarin shares are down 21%, or $3.66, to $14.15 in premarket trading. The potential three-month extension to the FDA action date does not impact Vascepa’s potentially multi-billion dollar peak sales opportunity, argues the analyst. Chen keeps an Overweight rating on Amarin with a $35 price target.